It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled ‘Long-term efficacy of tildrakizumab in European patients with moderate-to-severe plaque psoriasis from the 5-year reSURFACE 2 phase 3 trial‘ (P1754) at the EADV Virtual Congress, 29-31 October 2021.
- What is the rationale for the use of tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis? (0:08)
- Could you tell us a little about the reSURFACE 1 and reSURFACE 2 clinical studies and their findings? (0:26)
- What has the latest data taught us about the long-term efficacy and safety of tildrakizumab in this treatment setting? (1:05)
- How can we identify patients most likely to respond to tildrakizumab? (1:45)
- How does the efficacy and safety of tildrakizumab compare with other agents that also target IL-12, or specifically IL-17? (2:47)
Disclosures: Diamant Thaçi is a lecturer and/or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Biogen Idec, BIOCAD, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DS-Biopharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo Pharma, Eli Lilly, Novartis, Regeneron, Sandoz, Sanofi-Aventis and UCB, and received grants from AbbVie and Novartis (paid to institution).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
Share this Video
Related Videos In Psoriasis
Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!